Mandate

Vinge advises Wilson Therapeutics in connection with directed share issue

December 12, 2017

Vinge has advised Wilson Therapeutics on a directed new issue of shares, whereby Wilson Therapeutics raises proceeds of approximately SEK 244 million, before issue costs.

The share issue is directed to a number of selected institutions and sector specialist funds, internationally and in Sweden, on the basis of an accelerated bookbuilding process.

Vinge’s team consisted of Christian Lindhé, Erik Sjöman, Mattias Sköld, Ludvig Frithiof and Astrid Karlsson.

Related

Vinge advised Dr Schär

Vinge advised Dr Schär in the acquisition of Semper AB:s glutenfree business Dr. Schär, an Italian based company, is a developer of product for special nutritional needs.
February 29, 2024

Vinge advises Irisity AB in connection with the acquisition of Ultinous and a directed share issue

Vinge advises Irisity AB in connection with the acquisition of Ultinous and a directed share issue
February 29, 2024

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (publ) ("SBB") in connection with SBB establishing a joint venture company for community properties together with Castlelake, LP ("Castlelake").

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (publ) ("SBB") in connection with SBB establishing a joint venture company for community properties together with Castlelake, LP ("Castlelake").
February 29, 2024